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Hypothalamic gonadotropin releasing hormone (GnRH) is a key player in normal puberty and sexual development and function.
Genetic causes of isolated hypogonadotropic hypogonadism (IHH) have been identiﬁed during the recent years aﬀecting the syn-
thesis,secretion,oractionofGnRH.DevelopmentaldefectsofGnRHneuronsandtheolfactorybulbareassociatedwithhyposmia,
rarelyassociated with theclinical phenotypes of synkinesia,cleft palate, ear anomalies,or choanal atresia,and may bedueto muta-
tions of KAL1, FGFR1/FGF8, PROKR2/PROK2, or CHD7. Impaired GnRH secretion in normosmic patients with IHH may be
caused by deﬁcient hypothalamic GPR54/KISS1, TACR3/TAC3, and leptinR/leptin signalling or mutations within the GNRH1
gene itself. Normosmic IHH is predominantly caused by inactivating mutations in the pituitary GnRH receptor inducing GnRH
resistance, while mutations of the β-subunits of LH or FSH are very rare. Inheritance of GnRH deﬁciency may be oligogenic, ex-
plainingvariablephenotypes.Futureresearchshouldidentifyadditionalgenesinvolvedinthecomplexnetworkofnormalanddis-
turbed puberty and reproduction.
1.Introduction
Normalpubertaldevelopmentandreproductivefunctionde-
pends on the intact release and action of hypothalamic gon-
adotropin releasing hormone (GnRH). As a precondition,
distinct developmental and functional procedures involving
the coordinated action of other hypothalamic hormone-re-
ceptor systems are required for GnRH disposal. The detailed
diagnostic workup of patients with absent or incomplete
pubertal development due to gonadotropin deﬁciency has
recently led to the identiﬁcation of new genetic causes of iso-
lated hypogonadotropic hypogonadism (IHH) [1–7]. These
ﬁndings currently improve our understanding of how the
onsetandcourseofpubertyandreproductionarecontrolled.
The precise classiﬁcation of the underlying defect in the pa-
tient with IHH may, in turn, improve the clinical manage-
ment including choice and timing of therapeutic interven-
tion.
2. Normal Onsetof Puberty
The hypothalamic GnRH pulse generator constitutes the
basis of the CNS control of puberty. GnRH secretion is sup-
pressed during childhood via inhibitory neurotransmitters,
mainly gamma aminobutyric acid (GABA) and opioid pep-
tides [8]. After a rest period from approximately two until 8
to 9 years of age, declining inhibitory components and am-
plifyingexcitatorytransmittersincludingglutamateandkiss-
peptin enhance GnRH secretion.
The pubertal increase in GnRH secretion is initiated
and prompted by changes in transsynaptic and glial inputs
to the GnRH neuronal network [8]. Kisspeptins coordinate
environmental and metabolic factors for regulation of the
hypothalamic-pituitary-gonadal axis through modulation of
GnRH, LH, and FSH secretion and steroid feedback [9].
The pulsatile GnRH release from GnRH-containing neurons
with frequency and amplitude modulation is the main2 International Journal of Endocrinology
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Figure 1: Genetic control of pubertal development. Diﬀerent levels of GnRH and gonadotropin deﬁciency due to genetic disorders. (1)
Developmental defects of GnRH neurons due to disturbed neuronal migration and diﬀerentiation cause aplasia of GnRH neurons and
olfactory tract. (2) Impaired GnRH synthesis or secretion is found in the context of functional disorders within the hypothalamus or the
GnRH neuron itself. (3) GnRH resistance is caused by inactive GnRH receptor variants localised within the anterior pituitary gland. (4)
Gonadotropin deﬁciency may be due to defect synthesis of LH or FSH β-subunits.
determinant of system activation with progression into and
through puberty.
The stimulatory decapeptide GnRH binds in a hairpin
structure to its transmembrane receptor expressed in pitu-
itary gonadotrope cells [10]. The amino- and carboxy-termi-
nal domains of GnRH contribute to receptor binding and
activation via extracellular and transmembrane domains in-
ducing conformational changes and signal transduction,
thereby inducing synthesis and secretion of luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH). These
gonadotropins bind to their speciﬁc receptors in gonads and
stimulate synthesis of estrogens and testosterone resulting in
clinical signs of puberty. The functional integrity of this
hypothalamic-pituitary-gonadal system is the precondition
for normal reproductive function [9].
3. Causesof IsolatedNormosmic
Hypogonadotropic Hypogonadism and
Kallmann’sSyndrome
IHHischaracterisedbyimpairedgonadotropinreleaseinthe
contextofotherwisenormalanatomicalandfunctionalante-
rior pituitary function. Serum concentrations for LH, FSH,
and sex steroids are inappropriately low in the patient with
hypogonadism. Clinical signs and symptoms of hypogona-
dism include bilateral cryptorchidism in males, absent or
incomplete puberty with amenorrhea in females, and infer-
tility. The underlying cause may be due to developmental
defects of GnRH neurons, impaired functional activity
within GnRH neurons, disturbed interaction between the
GnRH ligand and its receptor, or the release of intact gon-
adotropins (Figure 1).
While aplasia of GnRH neurons occurs in the context
of developmental defects of the olfactory bulb, the clinical
symptom of anosmia indicates this kind of GnRH deﬁciency
[4, 5, 11–15]. Kallmann’s syndrome accounts for 50–52% of
cases with IHH, while normosmic IHH is found in 48–50%
of cases [16, 17]. Disorders of GnRH release have recently
been identiﬁed as rare causes of GnRH deﬁciency in patients
with normosmic IHH [2, 3, 7], while inactivating mutations
of the GnRH receptor are the most frequent cause for nor-
mosmic IHH, especially in familial cases [12, 17–21].
4. Developmental Abnormalities of GnRH
Neurons and Anosmia
Developmental defects of the olfactory bulb and GnRH sec-
reting neurons in patients with Kallmann’s syndrome are
caused by genetic alterations regulating the migration of
GnRH neurons from the forebrain to the hypothalamus
(Table 1).TheKAL1encodedprotein,anosmin-1,isanadhe-
sion protein involved in synaptogenesis, cell adhesion, and
olfactory axonal attraction and olfactory bulb morphogene-
sis[22].DeletionsandmutationsofKAL1 accountforappro-
ximately 10% of Kallmann’s syndrome patients [16, 17, 23].
IndividualswithKAL1mutationsmaypresentwithaddition-
al symptoms such as bimanual synkinesia characterised
by involuntary “mirror movements” (Figure 2) and renalInternational Journal of Endocrinology 3
Table 1: Genetic causes of Kallmann’s syndrome (KS) and normosmic isolated hypogonadotropic hypogonadism (IHH).
Gene Gene product Function Inheritance Clinical phenotype Associated clinical phenotype
KAL1 Anosmin-1 Cell adhesion X-linked KS Anosmia, bimanual synkinesis,
renal agenesis
FGFR1 Fibroblast-growth-factor
receptor 1
Tyrosine kinase
receptor AD KS or IHH Anosmia, cleft lip or palate, ear
anomalies, tooth agenesis
FGF8 Fibroblast growth factor 8 Ligand of FGFR1 AD KS or IHH
NELF Nasal embryonic LHRH
factor
Neuronal
migration AD KS Anosmia
CHD7
Chromodomain-
helicase-DNA-binding
protein 7
DNA-binding
protein, neural
crest development
AD KS or IHH
CHARGE syndrome: anosmia,
coloboma, heart anomaly,
choanal atresia, retardation, ear
abnormalities
PROKR2 Prokineticin receptor 2 GPCR AD
AR KS or IHH Anosmia
PROK2 Prokineticin 2 Ligand of PROKR2 AD
AR KS or IHH Anosmia
WDR11 WD protein Interaction with
EMX1 AD KS or IHH Anosmia
GPR54/KISS1R Kisspeptin-1 receptor GPCR AR IHH None
TACR3 Neurokinin B receptor GPCR AR IHH None
TAC3 Neurokinin B Ligand of TACR3 AR IHH None
LEPR leptin receptor
Single
transmembrane-
domain
receptor
AR IHH Obesity
LEP leptin Fat-regulating
hormone AR IHH Obesity
GNRH1 GnRH Release of LH and
FSH AR IHH None
GNRHR GnRH receptor GPCR AR IHH None
LHββ -subunit of LH Ligand of LH/CG
receptor AR IHH None
FSHββ -subunit of FSH Ligand of FSH
receptor AR IHH None
GPCR: heptahelical transmembrane G-protein-coupled receptor, AD: autosomal dominant.
AR: autosomal recessive.
agenesis [16]. Since KAL1 is a X-linked gene, familial Kall-
mann’s syndrome occurring only in males suggests a KAL1
defect.
The ﬁbroblast growth factor receptor (FGFR1) gene en-
codes a tyrosine kinase receptor involved in olfactory bulb
development and GnRH neurite outgrowth via FGF signall-
ing and the interaction between FGFR1 and anosmin-1
[22,24].Inactivatingmutationsofthisreceptorandoneofits
ligands,ﬁbroblastgrowthfactor8(FGF8),havebeendescrib-
ed in patients with variable degree of hypogonadism mainly
with and in few cases without anosmia [4, 14, 15, 22, 25, 26].
In very few subjects with FGFR1 mutations, a complete re-
versal of GnRH deﬁciency has been reported [27–29]. Addi-
tionalclinicalsignsobservedintheseindividualsincludecleft
palateorlip,earanomalies,andtoothagenesis[4,15,25,29].
Heterozygous mutations and deletions of the FGFR1/ FGF8
system account for approximately 10% of Kallmann’s syn-
drome and normosmic idiopathic hypogonadotropic hypog-
onadism [14, 25, 26].
Figure 2: Kallmann’s Syndrome. Synkinesia in a patient with KAL1
mutation (c.120 121insC; 122 127del, p.Ala41Glyfs43). When clos-
ingabookwithonehand(arrow),typicalinvoluntarymirrormove-
ment (synkinesia) of the other hand is observed (dotted arrow).
This 15-year-old boy presented because of absent puberty. There
was orchidopexy at the age of 2 years, disturbed spatial orienta-
tion, retarded ﬁne-motor developmental milestones, and anosmia.
Tanner P1, G1. LH <0.1U/L, FSH 0.4U/L, testosterone 0.2ng/mL.
During GnRH stimulation test, LH 0.5U/L, FSH 2.1U/L after 60
minutes. Cranial MRI revealed agenesis of olfactory bulbs and a
normal-sized pituitary gland.4 International Journal of Endocrinology
The prokineticin receptor 2 (PROKR2), a heptahelical
transmembrane G protein-coupled receptor, and its ligand
prokineticin 2 (PROK2) are expressed within the CNS in-
cluding olfactory system, arcuate nucleus, suprachiasmatic
nuclei,andmedianeminence[30,31].ThePROKR2/PROK2
system is involved in olfactory bulb development and in
GnRH neuron migration [32]. Heterozygous, compound
heterozygous and homozygous inactivating mutations have
been described within the PROKR2/PROK2 system, accou-
nting for less than 10% of individuals with Kallmann’s syn-
dromeandnormosmicGnRHdeﬁciency[5,32–34].Onepa-
tient with a heterozygous PROKR2 mutation has been re-
ported with reversal of hypogonadism after treatment with
testosterone [28, 34].
The human nasal embryonic LHRH factor (NELF) gene
is a candidate gene for Kallmann’s syndrome because of its
association with axonal guidance of olfactory and GnRH
neurons in mice [35]. Heterozygous mutations within the
NELF gene have been reported in few patients with Kall-
mann’ssyndrome[36–38].Sofar,theroleofNELFinhuman
reproduction is unclear, but NELF may be a critical modiﬁer
gene that orchestrates GnRH deﬁciency in conjunction with
other pathogenic genes [36].
Mutations within the chromodomain helicase DNA-
binding protein 7 (CHD7) have been identiﬁed in patients
with CHARGE association, a syndrome in which hypogona-
dotropic hypogonadism and hyposmia are associated with
choanal atresia, coloboma of the iris (Figure 3), cardiovas-
cular malformations, retardation of mental and somatic de-
velopment, and ear anomalies [13, 39]. Recently, CHD7 het-
erozygous mutations have been identiﬁed in subjects with
hypogonadotropic hypogonadism, with and without anos-
mia [40]. Patients presenting some of the CHARGE syn-
drome features are more likely to carry CHD7 mutations
[41]. CHD7 mutations are found in 5 to 10% of subjects ini-
tiallyclassiﬁedasKallmann’ssyndromeandnormosmicIHH
patients [40, 41].
Veryrecently,heterozygousmutationsofWDR11,encod-
ing a WD protein interacting with the transcription factor
EMX1, have been identiﬁed in six patients with Kallmann’s
syndrome or idiopathic hypogonadotropic hypogonadism
[42]. The interaction between WDR11 and EMX1 is critical
forthe development of olfactoryneurons whileWDR11 mis-
sense alterations reduce or abolish this interaction [42]. It
was concluded from these results that disturbed pubertal de-
velopment in these patients is caused by deﬁcient WDR11
protein interaction [42].
5.Defects of GnRHRelease andSynthesis
TheidentiﬁcationofinactivatingmutationswithintheG-pro
tein-coupled receptor 54 (GPCR54/KISSR) gene has demon-
strated the role of kisspeptin, the ligand of GPR54, in the
control of GnRH secretion [2, 3, 43–45]( Table 1). GPR54/
KISSR is a heptahelical transmembrane receptor, expressed
at the surface of GnRH neurons. GPR54 activation via kiss-
peptin induces GnRH secretion [9]. Neuroendocrine proﬁles
of subjects with GPR54/KISSR mutations revealed low
Figure 3: Iris coloboma as a typical characteristic of CHARGE syn-
drome. A woman with hypogonadotropic hypogonadism and
CHARGE syndrome (CHD7 mutation c.4787A>G, p.Asp1596Gly)
initially presented at the age of 16 years because of absent puberty.
There was a history of choanal atresia, deafness, learning disorders,
and anosmia. Tanner B1, P2. LH 0.2U/L, FSH 0.54U/L, estradiol
24pg/mL. During GnRH stimulation test, LH 1.61U/L, FSH
1.86U/L.
amplitude of LH pulses, suggesting low degree of endogen-
eous GnRH secretion [3, 46]. Male patients may present at
birth with micropenis and cryptorchidism and undetectable
gonadotropin levels [43, 46]. GPR54/KISSR mutations
account for 2–5% of normosmic IHH [2, 3, 43]. Until now,
mutations within the gene of the ligand of GPR54/KISSR,
KISS1, have not been described in patients with IHH.
Very recently, homozygous loss-of-function mutations
in TAC3, encoding neurokinin B and its heptahelical trans-
membrane G-protein-coupled receptor TACR3, have been
detected in patients with normosmic IHH [7, 47, 48]. Aﬀect-
ed subjects showed very low basal LH secretion with nonpul-
satilepatternwhilepulsatileGnRHtreatmentnormalisedLH
release and circulating sex steroids [47]. These ﬁndings indi-
catea crucialroleof NKB,viaits receptor NK3R,in hypotha-
lamic GnRH release [47]. The majority of male patients
withTACR3/TAC3mutationspresentedwithmicropenisand
lack or pubertal development while recovery of GnRH def-
iciency was observed in a signiﬁcant number of male and
female adult patients [48]. These observations support the
importance of the TACR3/TAC3 signaling during the neona-
tal period and puberty while its role seems less critical in
adulthood [48].
The role of leptin for pubertal development and repro-
duction has been demonstrated in leptin-null (ob/ob) mice
in which leptin administration accelerates puberty and nor-
malises reproductive dysfunction [49]. Leptin, encoded by
LEP, is a fat-derived hormone regulating food intake, energy
expenditure, and hypothalamic reproductive function. Inac-
tivating mutations in LEP or its receptor LEPR, a single
transmembrane-domain receptor of the cytokine receptor
family, have been described in patients with hypogonadism
and obesity [50–52]. These loss-of-function mutations are
rarecausesofnormosmicIHH.Treatmentwithrecombinant
leptin reconstitutes gonadotropin secretion and menstrual
cycles in females with amenorrhea due to congenital leptin
deﬁciency [53] or hypothalamic amenorrhea [54].
The most obvious candidate gene for patients with hypo-
gonadotropic hypogonadism was GnRH itself after descrip-
tion of the hypogonadal mouse model with homozygous
deletion within the GNRH1 gene [55, 56]. However, several
studies initially failed to identify GNRH1 gene mutations
in humans with hypogonadotropic hypogonadism [57, 58].International Journal of Endocrinology 5
Very recently, homozygous frameshift mutations within the
GNRH1 gene, encoding the preprohormone of GnRH, have
been identiﬁed in patients with IHH [6, 59]. In accordance
with the critical role of GnRH, male patients presented with
severe hypogonadism including micropenis. GNRH1 muta-
tionsarerarecausesofnormosmicisolatedGnRHdeﬁciency.
6.GnRHResistance and
Gonadotropin Deﬁciency
BindingofGnRHtoitsheptahelicaltransmembranereceptor
in the pituitary gland induces receptor activation and signal
transduction, ﬁnally resulting in secretion of gonadotropins.
Sincetheﬁrstdescriptionofloss-of-functionmutationinthe
GnRH receptor (GnRHR) [1], many inactivating mutations
have been found within the extracellular, transmembrane
and intracellular domains of the receptor [11, 19–21] leading
to impaired GnRH action (Figure 1). Depending on the
degree of functional impairment, these patients present with
complete absence of pubertal development or with incom-
plete puberty [19]. Loss-of-function mutations within the
GnRH receptor are the most frequent cause of autosomal-
recessiveIHH,accountingfor16%to40%ofpatients[18,21,
60]. Since these patients are resistant to GnRH, the eﬀective
fertility treatment is achieved with gonadotropins.
Mutations of the β-subunits of luteinizing hormone
(LH) or follicle-stimulating hormone (FSH) are rare causes
of hypogonadotropic hypogonadism. LH and FSH are
glycoproteinhormones,asthyroid-stimulatinghormoneand
human chorionic gonadotropin (hCG). These heterodimeric
hormones consist of a common α-subunit and a speciﬁc
β-subunit, encoded by separate genes. Females with inacti-
vating mutations of the LH β-subunit present with normal
puberty, with normal or late menarche followed by oligo-
or amenorrhea and infertility due to lack of ovulation [61].
Ovaries in aﬀe c t e dw o m e nm a yb ee n l a r g e dw i t hc y s t s[ 62].
Males with inactivating mutations of the LH β-subunit
have absent pubertal development due to testosterone deﬁ-
ciency and azoospermia in adulthood because of Leydig-cell
hypoplasia [61–63]. Testosterone replacement may result in
an increase of testicular volume in the context of high FSH
levels [61]. Individuals with inactivating FSHβ mutations
present with incomplete pubertal development and primary
amenorrhea in females and azoospermia in males [64–66].
Treatment with recombinant FSH induces ovulation but was
associated with signs of ovarian hyperstimulation which may
be explained by high pretreatment LH levels [67].
7. ClinicalImplications
Since pulsatile GnRH secretion is required for descent of the
testisinthemalefetus,patientswithgonadotropindeﬁciency
during fetal life may present with cryptorchidism and vari-
able degree of male undervirilisation. Additional symptoms
such as impaired sense of smell, bilateral synkinesia, cleft
palate, or choanal atresia are suspicious for speciﬁc con-
genital diseases associated with GnRH deﬁciency (Table 1).
Absent or incomplete pubertal development leading to
detailed diagnostic workup may identify congenital GnRH
or gonadotropin deﬁciency.
Hormonal replacement therapy during adolescence is
frequently delayed, although earlier signs and symptoms of
the patient would have predicted hypogonadotropic hypog-
onadism. Since hormonal induction of puberty does not
always require the deﬁnite identiﬁcation of the underlying
causeofGnRHorgonadotropindeﬁciency,someindividuals
areinvestigatedonlylaterinlifebecauseofinfertility.Inmost
cases of IHH, gonadotropin treatment induces ovulation
and spermatogenesis [68, 69], while patients with inactive
GnRHR variants will not respond to normal doses of GnRH
treatment [70, 71]. This GnRH resistance has been overcome
with higher GnRH doses in one subject with partially inacti-
vated GnRH receptor mutations [72].
In addition to absent or incomplete pubertal develop-
ment and infertility, further clinical variants of GnRH and
gonadotropin deﬁciency associated with genetic variants
have been recently observed. These variants include adult-
onset idiopathic hypogonadotropic hypogonadism [73],
functional hypothalamic amenorrhea [74], and spontaneous
reversals of well-established GnRH deﬁciency following
long-term therapy with testosterone [28]. Although the
mechanisms of reversal of hypogonadotropic hypogonadism
are unclear, it is speculated that GnRH neuron plasticity in
adults may be modulated by sex steroids [28]. Brief discon-
tinuation of hormonal replacement may, therefore, be rea-
sonable to assess if hypogonadotropic hypogonadism is re-
versible or persistent [28].
After a detailed individual and family history and physi-
cal examination evaluating the degree of hypogonadism and
presence of associated clinical symptoms (e.g., Figures 2
and 3), a molecular genetic analysis enables in many cases
deﬁnition of the underlying defect. Monogenic, digenic, or
even oligogenic inheritance of GnRH deﬁciency has been
observed explaining the variable phenotypic spectrum [17,
28, 36]. Alterations in two or more distinct genes in one
patient may induce a more severe phenotype than a single-
gene mutation and lead to the overlap of two or more clinical
syndromes. Rare genetic variants may further contribute
to the susceptibility of individuals to functional changes
in GnRH secretion such as hypothalamic amenorrhea, a
common multifactorial disease [74]. Genetic counselling is
oﬀered in case of genetic diagnosis to ﬁrst-degree family
members. However, approximately 60–70% of cases with
Kallmann’s syndrome and 50% of patients with normosmic
IHH are of unknown origin [60]. These patients and families
should be encouraged to participate in ongoing research
projects including DNA biobanking. In any case, early diag-
nosis of GnRH deﬁciency during childhood represents the
requisite for induction of puberty in due time.
8. Hormonal Treatment of IHH
The hormonal induction of puberty in a hypogonadal adole-
scent aims to mimic normal pubertal development. Hor-
monereplacementinadolescentsisusuallyinitiatedwithlow
dose of sex steroids and augmented over 3 to 5 years until6 International Journal of Endocrinology
mature status is reached. In girls, estradiol orally is preferred,
starting with one-sixths of the adult dose daily, increasing
every 6 months by 1/6 and adding gestagens from the
second year on day 1 to 12 of each month [75–77]. In boys,
testosterone replacement is initiated most frequently with
testosterone enanthate 50mg per month intramuscularly,
with increasing dose every 6 months until 250mg is given
every 3 weeks in the third year. While testosterone treatment
eﬀectivelyinducesvirilisationincludingpenilegrowth,pubic
and male hair and beard growth, change of voice, libido, and
pubertalgrowthspurt,testicularvolumeremainssmall,lack-
ing spermatogenesis. LH stimulates intratesticular testos-
terone secretion by Leydig cells inhibiting Anti-M¨ uller’s hor-
mone production of the Sertoli cells, FSH induces testis
growth via proliferation of seminiferous tubules, and both
stimulate Inhibin B secretion by the Sertoli cells and sperm
maturation. Therefore, induction of puberty using gon-
adotropins or pulsatile GnRH seems a more physiologic ap-
proach in the adolescent with hypogonadotropic hypogo-
nadism and has been successfully used [78–82]. To further
assess the beneﬁt of GnRH or gonadotropin treatment for
pubertal induction, prospective randomised trials are need-
ed.
During adulthood testosterone replacement may be con-
tinued by daily transdermal application of testosterone gel or
injection of the long-acting testosterone undecanoate intra-
muscularly every 3 months. Fertility treatment usually
requires gonadotropin treatment with hCG and FSH or may
alternatively, initiated by pulsatile GnRH treatment [80–82].
GnRH given every 90 minutes by a subcutaneous placed
pump is the most physiologic therapy of GnRH deﬁciency,
except in case of GnRH resistance, but is associated with
highercostsandtechnicalsupport.Inrarecasesofleptindef-
iciency, speciﬁc leptin treatment has been eﬀective for treat-
ment of hypogonadism [53, 54]. In general, long-term re-
placement of sex steroids is required not only for sexual and
reproductivefunctionbutalsoforbonehealthandmetabolic
(glucoseandfat)integrityinpatientswithhypogonadotropic
hypogonadism.
9. Conclusion
The discovery of new genetic causes of hypogonadotropic
hypogonadism gave new insights into the regulation of pub-
erty and reproduction in humans. With the identiﬁcation
of genetic variants in GnRH-deﬁcient patients, it became
clear that monogenic, digenic, and oligogenic traits of
inheritance may explain the variable phenotypic spectrum.
In more than 50% of patients with IHH, the underlying
defect is still unknown, demonstrating the need for further
research activity in this ﬁeld. The precise diagnosis facilitates
appropriate treatment and counselling in aﬀected patients.
Established treatment procedures for hormonal induction of
puberty might be reconsidered, since pulsatile GnRH and
gonadotropin treatment are eﬀective and more physiologic
alternatives.Toinvestigatethebeneﬁtofdiﬀerenttherapeutic
options on quality of life and fertility, prospective ran-
domised controlled trials with long-term followup have to
be conducted. For these future research directions, national
andinternationalscientiﬁcnetworkingwillbeadvantageous.
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